Literature DB >> 15291982

Primary central nervous system lymphoma.

Igor T Gavrilovic1, Lauren E Abrey.   

Abstract

Primary central nervous system lymphoma (PCNSL) is a rare variant of non-Hodgkin's lymphoma that is increasing in incidence. Methotrexate-based chemotherapy in combination with whole-brain radiotherapy (WBRT) has dramatically improved the outcome of patients. However, treatment-related neurotoxicity is a significant complication, especially after radiotherapy in the elderly. Despite advances in therapy, several important questions remain regarding optimal methotrexate dose, dosing frequency, adjunct chemotherapy, and the impact of deferring WBRT. Advances in biologic therapy and strategies to intensify the delivery of chemotherapy may help to limit the use of radiotherapy, thus lessening potential neurotoxicity. Studies looking at oncogenic proteins as potential prognostic markers for PCNSL may help us to develop risk-adapted therapies.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15291982     DOI： 10.1007/s11912-004-0065-7

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  57 in total

1.  Primary lymphoma of the central nervous system: typical and atypical CT and MR imaging appearances.

Authors:  N Erdag; R M Bhorade; R A Alberico; N Yousuf; M R Patel
Journal:  AJR Am J Roentgenol       Date:  2001-05       Impact factor: 3.959

2.  International Collaborative Group against Primary CNS Lymphomas.

Authors:  Andres J M Ferreri; Tracy Batchelor; Emanuele Zucca; Franco Cavalli; James Armitage
Journal:  J Clin Oncol       Date:  2003-04-15       Impact factor: 44.544

3.  Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma.

Authors:  L D McAllister; N D Doolittle; P E Guastadisegni; D F Kraemer; C A Lacy; J R Crossen; E A Neuwelt
Journal:  Neurosurgery       Date:  2000-01       Impact factor: 4.654

4.  Primary malignant lymphomas of the central nervous system.

Authors:  J M Henry; R R Heffner; S H Dillard; K M Earle; R L Davis
Journal:  Cancer       Date:  1974-10       Impact factor: 6.860

5.  Epidemiology of brain lymphoma among people with or without acquired immunodeficiency syndrome. AIDS/Cancer Study Group.

Authors:  T R Coté; A Manns; C R Hardy; F J Yellin; P Hartge
Journal:  J Natl Cancer Inst       Date:  1996-05-15       Impact factor: 13.506

6.  Pathology with clinical correlations of primary central nervous system non-Hodgkin's lymphoma. The Massachusetts General Hospital experience 1958-1989.

Authors:  D C Miller; F H Hochberg; N L Harris; M L Gruber; D N Louis; H Cohen
Journal:  Cancer       Date:  1994-08-15       Impact factor: 6.860

7.  Epidemiology of primary CNS lymphoma.

Authors:  M Schabet
Journal:  J Neurooncol       Date:  1999-07       Impact factor: 4.130

8.  Cerebral lymphoma presenting as a nonenhancing lesion on computed tomographic/magnetic resonance scan.

Authors:  L M DeAngelis
Journal:  Ann Neurol       Date:  1993-03       Impact factor: 10.422

9.  Combined modality therapy for primary CNS lymphoma.

Authors:  L M DeAngelis; J Yahalom; H T Thaler; U Kher
Journal:  J Clin Oncol       Date:  1992-04       Impact factor: 44.544

10.  Primary central nervous system lymphomas in 72 immunocompetent patients: pathologic findings and clinical correlations. Groupe Ouest Est d'étude des Leucénies et Autres Maladies du Sang (GOELAMS)

Authors:  S Camilleri-Broët; A Martin; A Moreau; R Angonin; D Hénin; M F Gontier; M C Rousselet; S Caulet-Maugendre; P Cuillière; T Lefrancq; K Mokhtari; M Morcos; P Broët; M Kujas; J J Hauw; B Desablens; M Raphaël
Journal:  Am J Clin Pathol       Date:  1998-11       Impact factor: 2.493
View more
  1 in total

1.  [Primary central nervous system lymphoma in elderly patients--a therapeutical challenge].

Authors:  Mario Molnar
Journal:  Wien Med Wochenschr       Date:  2008
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.